Selskabsmeddelelse26.6.2024, 09.00Redwood Pharma provides a new update regarding divestment of company assets
Pressemeddelelse12.6.2024, 10.00Redwood Pharma provides an update on the process for divesting the company's assets
Pressemeddelelse8.5.2024, 06.30Redwood Pharma's product RP501 attracted a lot of interest at ARVO in Seattle
Pressemeddelelse7.5.2024, 06.30Two international companies begin due diligence on Redwood Pharma's product RP501 ahead of potential commercial agreements
Pressemeddelelse28.2.2024, 07.30Redwood Pharma's innovative dry eye treatment to be presented at ARVO in Seattle
Pressemeddelelse19.12.2023, 07.00Redwood Pharma to participate in the JP Morgan Healthcare Conference
Selskabsmeddelelse30.11.2023, 07.30Redwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)
Pressemeddelelse22.11.2023, 07.30Redwood Pharma to participate in the NLS Days partner conference in Copenhagen
Pressemeddelelse19.10.2023, 09.15Redwood Pharma to participate in the BIO-Europe partnering conference in Munich
Selskabsmeddelelse31.5.2023, 21.10Redwood Pharma presents positive results from a clinical study with RP501 against dry eye
Pressemeddelelse17.3.2023, 12.00Redwood Pharma completes recruitment for clinical trial with RP501 for dry eye
Pressemeddelelse24.1.2023, 07.30Redwood Pharma takes important steps towards the commercial production of its dry eye product
Selskabsmeddelelse15.12.2022, 16.00Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501
Pressemeddelelse19.10.2022, 13.18Interview with CEO Martin Vidaeus of Redwood Pharma at BioStock Investor Meeting, Stockholm
Pressemeddelelse14.10.2022, 06.30Redwood Pharma: Streamed video of CEO Martin Vidaeus presenting at Aktieportföljen Live in Stockholm, Sweden on Oct. 11, 2022
Pressemeddelelse3.10.2022, 13.42Redwood Pharma to present at AKTIEPORTFÖLJEN LIVE SVERIGE in Stockholm on 11[th] of Oct. 2022 at 14:45